Analysts’ Top Healthcare Picks: Arvinas Holding Company (ARVN), Schrodinger (SDGR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report) and Schrodinger (SDGR – Research Report) with bullish sentiments.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Arvinas Holding Company (ARVN)

Barclays analyst Etzer Darout maintained a Buy rating on Arvinas Holding Company today and set a price target of $15.00. The company’s shares closed last Friday at $9.61, close to its 52-week low of $7.53.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 23.2% and a 52.8% success rate. Darout covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Janux Therapeutics Inc, and Terns Pharmaceuticals. ;'>

Currently, the analyst consensus on Arvinas Holding Company is a Moderate Buy with an average price target of $20.46.

See today’s best-performing stocks on TipRanks >>

Schrodinger (SDGR)

Barclays analyst Peter Lawson maintained a Buy rating on Schrodinger today and set a price target of $24.00. The company’s shares closed last Friday at $20.59.

According to TipRanks.com, Lawson has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -5.4% and a 41.3% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Arvinas Holding Company. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Schrodinger with a $25.06 average price target, a 16.1% upside from current levels. In a report issued on October 2, Craig-Hallum also maintained a Buy rating on the stock.

Read More on ARVN:

Disclaimer & DisclosureReport an Issue

• Arvinas presents data from two Phase 1 trials for ARV-102
• Amazon upgraded, Adobe downgraded: Wall Street’s top analyst calls
• Arvinas downgraded to Neutral from Buy at BofA
• Arvinas Holding: Strategic Shifts and Cost Optimization Amidst Competitive SERD Landscape
• Arvinas Holding Company: Strategic Shifts and Growth Opportunities Drive Buy Rating